RxDoctor Payments Data

Byron Littlefield, DO

Family Medicine · Adairsville, GANPI 1447279740

Payments from drug & device makers

$5,768in general payments, 2019–2025

Across 332 payments — averaging $17.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Pfizer$685
  • Lilly USA, LLC$551
  • AbbVie$499
  • GSK$363
  • AstraZeneca$327
  • plus $2K from 38 others

What the payments were for

  • Food & beverage$5,71899%
  • Education$491%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,768 in reported general payments places this provider in the 85th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$85,787
Medicare patients
211
Services billed
1,581

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban212$175,789
MounjaroTirzepatide138$156,144
OzempicSemaglutide138$146,549
JardianceEmpagliflozin94$98,194
XareltoRivaroxaban73$81,404
RybelsusSemaglutide56$68,190
FarxigaDapagliflozin Propanediol71$62,146
TrulicityDulaglutide32$48,972
JanuviaSitagliptin Phosphate44$47,307
Trelegy ElliptaFluticasone/Umeclidin/Vilanter49$34,970
LinzessLinaclotide29$18,973
InvokanaCanagliflozin18$16,107
QuliptaAtogepant13$15,482
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog25$15,364
Breo ElliptaFluticasone/Vilanterol36$15,362

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,377$214,739194 claims
Lilly USA, LLCMounjaro, Trulicity$551$205,116170 claims
PfizerEliquis, Premarin$685$179,592231 claims
Boehringer IngelheimJardiance, Spiriva Respimat$114$107,313106 claims
Johnson & JohnsonXarelto, Invokana$27$97,51191 claims
AstraZenecaFarxiga, Brilinta, Symbicort, Daliresp$327$88,597137 claims
GSKTrelegy Ellipta, Breo Ellipta$363$50,33285 claims
MerckJanuvia$117$47,30744 claims
AbbVieLinzess, Qulipta, Synthroid$499$39,249105 claims
Astellas Pharma US IncMyrbetriq$55$8,40919 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Adairsville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →